Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Latigo Biotherapeutics Q3 2026 Results: Net Loss of $20.9M, Loss Narrows

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company that has incurred an accumulated deficit of $312.8 million as of September 30, 2026. The company is focused on developing its lead product candidates, onzotrigine and LTG-321, and anticipates continued substantial losses as it funds research and development.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-20.9-24.8
EPS (diluted, $ a share)$-0.55$-29.50

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: LTGO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Latigo Biotherapeutics, Inc.: key numbers

Share price
$13.76Close, Nov 17
Market cap
$912M
Shares outstanding
66.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Latigo Biotherapeutics, Inc.

All →
7:09 AM ET 8-K
Financial Results

Latigo Biotherapeutics Financial Results

Latigo Biotherapeutics reported Q3 2026 financial results, ending the period with $401 million in cash to fund operations into 2029. The company also announced the appointment of Todd Smith as President and CEO, replacing Nima Farzan, and updated its Phase 3 onzotrigine trial design to include a Percocet comparator arm.

Term
Q3 2026

“With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program.”

Todd N. Smith, president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.